Læknablaðið - 15.09.2004, Page 31

FRÆÐIGREINAR / SYKURSÝKI TEGUND
Með rannsókn okkar höfum við reynt að gefa
mynd af árangri meðferðar sykursjúkra tegund 2 eins
og hún er í dag á sérhæfðri göngudeild. Þótt saman-
burður við önnur lönd komi að mestu leyti vel út þá
eru niðurstöðurnar hvatning um að gera enn betur.
Heimildir
1. King H, Aubert RE, Herman WH. Global burden of diabet-
es, 1995-2025: prevalance, numerical estimate, and projection.
Diabetes Care 1998; 21:1414-31.
2. Laing W, Williams R. Diabetes: a model for health care manage-
ment. Office of Health Economics, London, 1989.
3. Ratner RE. Type 2 diabetes mellitus: the grand overview. Diabet
Med 1998; 15 (suppl 4): S4-S7.
4. Rubin RJ, Altman WM, Mendelson DN. Health care expend-
iture for people with diabetes mellitus 1992. J Clin Endocrinol
Metab 1994; 78: 809A-809F.
5. UK Prospective Diabetes Study (UKPDS) Group: Intensive
blood-glucose control with sulphonylureas or insulin compares
with conventional treatment and risk of complications in patients
with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
6. UK Prospective Diabetes Study (UKPDS) Group. Tight blood
pressure control and risk of macrovascular and microvascular
complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:
703-13.
7. Gæde P, Vedel P, Larsen N, Jensen GVH, Parving HH, Peders-
en O. Multifactorial Intervention and Cardiovascular Vascular
Disease in Patients with Type 2 Diabetes. N Engl J Med 2003;
348: 383-93.
8. Pyörala K, Pedersen TR, Kjekshus J, Færgeman O, Olsson AG,
Þorgeirsson G. Cholesterol lowering with simvastatin improv-
es prognosis of diabetic patients with coronary heart disease.
A subgroup analysis of the Scandinavian Simvastatin Survival
Study (4S). Diabetes Care 1997; 20: 614-20.
9. Shichiri M, Kishikaw H, Ohkubo Y, Wake N. Long term results
of the Kumamoto study on optimal diabetes control in type 2
diabetes patients. Diabetes Care 2000; 23 (suppl. 2): B21-29.
10. Friðriksson HV, Hreiðarsson ÁB, Stefánsson E, Geirsson RT,
Jónsdóttir JG, Ingólfsdóttir JG. Sykursýki á íslandi. Skýrsla gefin
út af heilbrigðis-og tryggingamálaráðuneytinu, október 1992.
11. Kristinsson JK. Diabetic retinopathy. Screening and prevention
of blindness. A doctoral thesis. Acta Ophthalmol Scand 1997;
Suppl(223): 1-76.
12. Hreiðarsson ÁB, Geirsson RT, Helgason Þ. Diabetes mellitus
in Iceland: prevalence, organization of services, pregnancy out-
come and long-term complications. Diab Nutr Metab 1993; 6:
333-4.
13. Björnsson H, Hreiðarsson ÁB, Benediktsson R, Gunnarsson R,
Einarsdóttir R, Þorgeirsson Ó. Sykursýki af tegund tvö, klínískar
leiðbeiningar. Læknablaðið 2002; 88: 832-4.
14. Alberti KGMM, Zimmet PZ. Definition, diagnosis and classific-
ation of Diabetes Mellitus and its Complications Part 1: Diagn-
osis and Classification of Diabetes Mellitus Provisional Report
ofWHO Consultation Diabetes Medicine 1998;15: 539-53.
15. Hoelzel W, Weykamp C, Jeppsson JO, Miedema K, Barr JR,
Goodall I, et al. IFCC reference system for measurement of
hemoglobin A,C in human blood and the national standardizat-
ion schemes in the United States, Japan and Sweden: a method-
comparison study. Clin Chem 2004; 50:166-74.
16. Gudbjörnsdóttir S, Cederholm J, Nilsson PM, Elíasson B; Steer-
ing Committee of the Swedish National Diabetes Register. The
National Diabetes Register in Sweden: an implementation of the
St. Vincent Declaration for Quality Improvement in Diabetes
Care. Diabetes Care 2003; 26:1270-6.
17. James P, Emslie-Smith AM, Brennan G, Libby A, Morris D. A
population-based comparison of treatment patterns and glycem-
ic control in Teyside region in Scotland for 1997 and for 2001.
Diabetologia 2003; 46: suppl 2.
18. Björnsdóttir G. Sykursýkilyf til inntöku og notkun þeirra á
íslandi. Kandídatsverkefni í lyfjafræði við Háskóla íslands árið
1987.
19. Hreiðarsson ÁB, Arnardóttir I, Ársælsdóttir BM, Helgason T.
Treating impaired glucose toleance with weight reduction long-
term results. International Symposium On Diabetes and Nutrit-
ion. Reykjavík 2000.
20. Hunter K, Connacher A, Cunningham G, Emslie-Smith AM,
Dutton A, Kramer G, et al. Are managed clinical networks ass-
ociated with improved clinical outcome? Diabetologia 2003; 46:
suppl 2.
21. The national board of health and welfare in Sweden. www.sos.se
22. Koskinen P, Manttari M, Manninen V. Coronary heart disease
incidence in NIDDM patients in the Helsinki Heart Study. Diab-
etes Care 1992; 15:820-5.
23. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifk-
ova R, Dallongeville J, et al. European guidelines on cardiovasc-
ular disease prevention in clinical practice. Eur Heart J 2003; 24:
1601-10.
24. Heart Protection Study Collaborative Group. MRC/BHF Heart
Protection Study of cholesterol-lowering with simvastatin in
5963 people with diabetes:a randomised placebo-controlled trial.
Lancet 2003; 361:2005-16.
25. Brennan GM, James P, Morris D, Emslie-Smith AM. Lipid-low-
ering therapy for secondary prevention of macrovascular disease
in a UK diabetes population. Comparison of practce with guide-
lines. Diabetologia 2003; 46: suppl 2.
26. Harrii MI. Health care and health status and outcome for pat-
ients with type 2 diabetes. Diabetes Care 2000; 23:754-8.
27. Williams R, Van Gaal L, Lucioni C. Assessing the impact of
complications on the costs of Type II diabetes. Diabetologia
2002; 45 (suppl 1): S13-S7.
28. Groop PH, Klaukka T, Reunanen A, Bergman U, Borch-Johns-
en U, Damsgaard EM, et al. Diabeteslákemedel i Norden, ana-
lys av orsaker till variation i forbruket. Folkepensionanstaltens
Publikationer. Helsingfors, 1991.
Læknablaðið 2004/90 627